/TNGX
TNGX Stock - Tango Therapeutics, Inc.
Healthcare|BiotechnologyNASDAQ
$8.52+0.71%
+$0.06 (+0.71%) • Dec 19
74
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.74
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.51
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+58.5%upside
Target: $13.50
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for TNGX
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$8.43 – $8.61
TARGET (TP)$13.50
STOP LOSS$7.84
RISK/REWARD1:7.3
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta1.72
52W High$11.20
52W Low$1.03
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $42.07M | $36.53M | $24.86M | $37.04M | $7.66M |
| Gross Profit | $42.07M | $36.53M | $24.86M | $37.04M | $6.03M |
| Gross Margin | 100.0% | 100.0% | 100.0% | 100.0% | 78.8% |
| Operating Income | $-145,595,000 | $-114,173,000 | $-111,071,000 | $-58,190,000 | $-52,200,000 |
| Net Income | $-130,302,000 | $-101,744,000 | $-108,176,000 | $-58,235,000 | $-51,972,000 |
| Net Margin | -309.7% | -278.5% | -435.1% | -157.2% | -678.8% |
| EPS | $-1.19 | $-1.08 | $-1.23 | $-0.94 | $-1.62 |
Company Overview
Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company also develops Ubiquitin-specific protease 1, an inhibitor to treat patients with BRCA1 or BRCA2-mutant cancers; and Target 3 for STK11-mutant cancers. Tango Therapeutics, Inc. has a strategic collaboration with Gilead Sciences, Inc. for the discovery, development, and commercialization of a pipeline of therapies for patients with cancer. The company was founded in 2017 and is based in Cambridge, Massachusetts.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
2
100%
Hold / Neutral
0%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
2 Bullish0 Neutral/Bearish
Price Targets
$16
Average Target
↑ 87.8% Upside
Now
$11
Low
$16
Average
$19
High
Based on 4 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| November 18th 2025 | Wolfe Research | Initiation | Peer Perform | - |
| August 19th 2025 | Piper Sandler | Initiation | Overweight | $11 |
| July 17th 2024 | Jefferies | Initiation | Buy | $19 |
| April 4th 2024 | Cantor Fitzgerald | Initiation | Overweight | - |
| February 12th 2024 | Piper Sandler | Initiation | Overweight | $18 |
| December 8th 2023 | B. Riley Securities | Initiation | Buy | $16 |
Earnings History & Surprises
TNGXBeat Rate
53%
Last 17 quarters
Avg Surprise
+77.2%
EPS vs Estimate
Beats / Misses
9/6
2 met exactly
Latest EPS
$0.13
Q4 2025
EPS Surprise History
Q1 24
-14.3%
$-0.32vs$-0.28
Q2 24
-12.9%
$-0.35vs$-0.31
Q3 24
+29.4%
$-0.24vs$-0.34
Q4 24
+20.6%
$-0.27vs$-0.34
Q1 25
-9.4%
$-0.35vs$-0.32
Q2 25
-5.9%
$-0.36vs$-0.34
Q3 25
0.0%
$-0.35vs$-0.35
Q4 25
+1200.0%
$0.13vs$0.01
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 11, 2026 | — | — | — | — |
Q1 2026 | Feb 26, 2026 | $-0.31 | — | — | — |
Q4 2025 | Nov 4, 2025 | $0.01 | $0.13 | +1200.0% | ✓ BEAT |
Q3 2025 | Aug 5, 2025 | $-0.35 | $-0.35 | 0.0% | = MET |
Q2 2025 | May 12, 2025 | $-0.34 | $-0.36 | -5.9% | ✗ MISS |
Q1 2025 | Feb 27, 2025 | $-0.32 | $-0.35 | -9.4% | ✗ MISS |
Q4 2024 | Nov 6, 2024 | $-0.34 | $-0.27 | +20.6% | ✓ BEAT |
Q3 2024 | Aug 7, 2024 | $-0.34 | $-0.24 | +29.4% | ✓ BEAT |
Q2 2024 | May 8, 2024 | $-0.31 | $-0.35 | -12.9% | ✗ MISS |
Q1 2024 | Mar 18, 2024 | $-0.28 | $-0.32 | -14.3% | ✗ MISS |
Q4 2023 | Nov 8, 2023 | $-0.34 | $-0.23 | +32.4% | ✓ BEAT |
Q3 2023 | Aug 7, 2023 | $-0.35 | $-0.23 | +34.3% | ✓ BEAT |
Q2 2023 | May 9, 2023 | $-0.36 | $-0.32 | +11.1% | ✓ BEAT |
Q1 2023 | Mar 27, 2023 | $-0.36 | $-0.33 | +8.3% | ✓ BEAT |
Q4 2022 | Nov 10, 2022 | $-0.32 | $-0.33 | -3.1% | ✗ MISS |
Q3 2022 | Aug 10, 2022 | $-0.33 | $-0.28 | +15.2% | ✓ BEAT |
Q2 2022 | May 11, 2022 | $-0.28 | $-0.29 | -3.6% | ✗ MISS |
Q1 2022 | Mar 28, 2022 | $-0.28 | $-0.25 | +10.7% | ✓ BEAT |
Q4 2021 | Nov 9, 2021 | $-0.28 | $-0.28 | 0.0% | = MET |
Q3 2021 | Aug 6, 2021 | — | $-0.05 | — | — |
Latest News
Stifel Initiates Coverage On Tango Therapeutics with Buy Rating, Announces Price Target of $15
📈 PositiveBenzinga•Dec 4, 2025, 04:58 PM•Also:
Tango Therapeutics shares are trading higher. The company announced it filed for a mixed shelf of up to $100 million.
📈 PositiveBenzinga•Nov 21, 2025, 05:05 PM
Tango Therapeutics Files For Mixed Shelf Of Up To $100M Common Stock
➖ NeutralBenzinga•Nov 21, 2025, 01:40 PM
Wolfe Research Initiates Coverage On Tango Therapeutics with Peer Perform Rating
➖ NeutralBenzinga•Nov 18, 2025, 05:19 PM
B. Riley Securities Maintains Buy on Tango Therapeutics, Raises Price Target to $14
📈 PositiveBenzinga•Nov 18, 2025, 05:07 PM
Tango Therapeutics' September 30 $152.8M In Cash, Cash Equivalents And Marketable Securities, in addition to $212M In October Financing Is Expected To Extend Cash Runway Into 2028
📈 PositiveBenzinga•Nov 4, 2025, 02:03 PM
Tango Therapeutics Q3 2025 EPS $0.14 Beats $(0.05) Estimate, Sales $53.811M Beat $37.142M Estimate
📈 PositiveBenzinga•Nov 4, 2025, 02:01 PM
Guggenheim Maintains Buy on Tango Therapeutics, Raises Price Target to $12
📈 PositiveBenzinga•Oct 24, 2025, 12:01 PM•Also:
Tango jumps on $225M funding and trial data for cancer drug
📈 PositiveSeeking Alpha•Oct 23, 2025, 01:08 PM
Tango Therapeutics rises on $225M financing
📈 PositiveSeeking Alpha•Oct 23, 2025, 11:33 AM
Tango Therapeutics Announces $225M Financing; Prices $210M Offering Of 21M Shares At $8.66 And 3.2M Pre-Funded Warrants At $8.659
📈 PositiveBenzinga•Oct 23, 2025, 11:23 AM
Tango Therapeutics' New Drug Doubles Response Rates in Deadly Pancreatic Cancer Trial
📈 PositiveBenzinga•Oct 23, 2025, 11:06 AM
Tango Therapeutics To Showcase Initial Clinical Results For TNG260 In Combination With Pembrolizumab In STK11-Mutant Lung Cancer At SITC Annual Meeting
📈 PositiveBenzinga•Oct 6, 2025, 11:09 AM
Piper Sandler Initiates Coverage On Tango Therapeutics with Overweight Rating, Announces Price Target of $11
📈 PositiveBenzinga•Aug 19, 2025, 11:51 AM
Frequently Asked Questions about TNGX
What is TNGX's current stock price?
Tango Therapeutics, Inc. (TNGX) is currently trading at $8.52 per share. The stock has moved +0.71% today.
What is the analyst price target for TNGX?
The average analyst price target for TNGX is $13.50, based on 1 analyst.
What sector is Tango Therapeutics, Inc. in?
Tango Therapeutics, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is TNGX's market cap?
Tango Therapeutics, Inc. has a market capitalization of $0.94 billion, making it a small-cap company.
Does TNGX pay dividends?
No, Tango Therapeutics, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorBCAX
Bicara Therapeutics Inc. Common Stock
$17.60
Mkt Cap: $1.0B
EYPT
EyePoint Pharmaceuticals, Inc.
$17.43
Mkt Cap: $1.2B
FTRE
Fortrea Holdings Inc.
$17.74
Mkt Cap: $1.6B
KOD
Kodiak Sciences Inc.
$26.00
Mkt Cap: $1.4B
KURA
Kura Oncology, Inc.
$9.84
Mkt Cap: $0.9B
NRIX
Nurix Therapeutics, Inc.
$18.52
Mkt Cap: $1.4B
PROK
ProKidney Corp.
$2.37
Mkt Cap: $0.3B
SEPN
Septerna, Inc.
$29.58
Mkt Cap: $1.3B
URGN
UroGen Pharma Ltd.
$22.80
Mkt Cap: $1.1B
XNCR
Xencor, Inc.
$15.55
Mkt Cap: $1.1B
Explore stocks similar to TNGX for comparison